Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

1.640 UNCHANGED
Streaming Delayed Price Updated: 7:52 AM EDT, Apr 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Fsd Pharma Inc Cl B

< Previous 1 2 3 Next >
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
From PR Newswire
FSD Pharma Commences Proceedings Against Dissident Shareholders
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced that it has commenced an application in the Ontario Superior Court seeking orders from the Court about the... 
From Business Wire News Releases
Proactive news headlines including FansUnite Entertainment, Renforth Resources, Tinka Resources and KULR Technology Group
Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: 
From GlobeNewswire News Releases
Thinking about buying stock in FSD Pharma, Onconova Therapeutics, Nabriva Therapeutics, Zosano Pharma, or Savara?
InvestorsObserver issues critical PriceWatch Alerts for HUGE, ONTX, NBRV, ZSAN, and SVRA. 
From PR Newswire
FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and Cats
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces that it has entered into a license agreement (the “License Agreement”) with Innovet Italia S.R.L. (“Innovet”),... 
From Business Wire News Releases
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Iss
From Newsfile Corp News Releases
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Iss
From PR Newswire
Thinking about buying stock in Gamida Cell, Co-Diagnostics, T2 Biosystems, FSD Pharma, or Allena Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for GMDA, CODX, TTOO, HUGE, and ALNA. 
From PR Newswire
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
From ACN Newswire
FSD Pharma Announces US$20M At-The-Market Offering
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that it has entered into an Equity Distribution Agreement dated February 11, 2021 (the "Sales Agreement") with... 
From Business Wire News Releases
Thinking about buying stock in AC Immune, Sundial Growers, FSD Pharma, Intec Pharma, or Northern Dynasty Minerals?
InvestorsObserver issues critical PriceWatch Alerts for ACIU, SNDL, HUGE, NTEC, and NAK. 
From PR Newswire
Thinking about buying stock in Sundial Growers, Neptune Wellness Solutions, Gamida Cell, FSD Pharma, or Salarius Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for SNDL, NEPT, GMDA, HUGE, and SLRX. 
From PR Newswire
FSD Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announces the following corporate updates. 
From Business Wire News Releases
FSD Pharma Sets Date for Annual Meeting
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. 
From Business Wire News Releases
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced the dosing of the first patient in its Phase 2a clinical trial of FSD201 (ultramicronized... 
From Business Wire News Releases
FSD Pharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (“FSD Pharma” or the “Company”) today announced its financial results for the third quarter ending September 30, 2020 and provided a corporate update. The... 
From Business Wire News Releases
FSD Pharma Announces Settlement of Class Action Proceeding
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) ("FSD Pharma" or the "Company") today announced that, subject to court certification and other customary conditions, it has entered into a definitive settlement... 
From Business Wire News Releases
FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering
FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B... 
From Business Wire News Releases
FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering
FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate... 
From Business Wire News Releases
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has authorized the initiation of a Phase 2 study for the use... 
From Business Wire News Releases
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
From ACCESSWIRE
Thinking about buying stock in Aimmune Therapeutics, FSD Pharma, Amarin Corp, Trevena Inc, or American Airlines?
InvestorsObserver issues critical PriceWatch Alerts for AIMT, HUGE, AMRN, TRVN, and AAL. 
From PR Newswire
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
From ACCESSWIRE
FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) an Investigational New Drug... 
From Business Wire News Releases
FSD Pharma Reports Second Quarter 2020 Financial Results
From ACCESSWIRE
FSD Pharma Reports Second Quarter 2020 Financial Results
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations... 
From Business Wire News Releases
FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors
From ACCESSWIRE
FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) announces the closing of a previously announced agreement with investors for the purchase and sale of 2,762,430 Class B... 
From Business Wire News Releases
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video
From Newsfile Corp News Releases
FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
From ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.